Third and fourth generation fluoroquinolone antibacterials: A systematic review of safety and toxicity profiles

Current Drug Safety

Volumn 9, Issue 2, 2014, Pages 89-105

  Sousa, Joana ^a,b   Alves, Gilberto ^b,c   Fortuna, Ana ^a,b   Falcão, Amílcar ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

Adverse effects; Fluoroquinolones; Structure activity relationship; Toxicity

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; BESIFLOXACIN; CIPROFLOXACIN; CLARITHROMYCIN; CLINAFLOXACIN; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; PAZUFLOXACIN; PIPERAZINE; QUINOLONE DERIVATIVE; SITAFLOXACIN; SPARFLOXACIN; TEMAFLOXACIN; TOSUFLOXACIN; TROVAFLOXACIN; ULIFLOXACIN;

ADVERSE DRUG REACTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHROPATHY; ARTICLE; CARDIOTOXICITY; DRUG SAFETY; DRUG TOLERABILITY; DYSGLYCEMIA; GASTROINTESTINAL DISEASE; GRAM POSITIVE BACTERIUM; HUMAN; LIVER TOXICITY; NEUROTOXICITY; NONHUMAN; PHOTOTOXICITY; PRIORITY JOURNAL; QT PROLONGATION; SKIN MANIFESTATION; STRUCTURE ACTIVITY RELATION; SYSTEMATIC REVIEW; TENDINITIS; CHEMICALLY INDUCED; DERMATITIS, PHOTOTOXIC; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; ELECTROCARDIOGRAPHY; EYE DISEASE; GASTROINTESTINAL TRACT; NEUROTOXICITY SYNDROMES; SKIN DISEASE;

ANTI-BACTERIAL AGENTS; DERMATITIS, PHOTOTOXIC; DRUG-INDUCED LIVER INJURY; ELECTROCARDIOGRAPHY; EYE DISEASES; FLUOROQUINOLONES; GASTROINTESTINAL TRACT; HUMANS; NEUROTOXICITY SYNDROMES; SKIN DISEASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84904717224     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574886308666140106154754     Document Type: Article

References (125)

1. Stahlmann R, Lode HM. Risks associated with the therapeutic use of fluoroquinolones. Expert Opin Drug Saf 2013; 12(4): 497-505.
2. Etminan M, Forooghian F, Brophy JM, Bird ST, Maberley D. Oral fluoroquinolones and the risk of retinal detachment. AMA 2012; 307(13): 1414-9.
3. Hall MM, Finnoff JT, Smith J. Musculoskeletal complications of fluoroquinolones: guidelines and precautions for usage in the athletic population. PMR 2011; 3(2): 132-42.
4. Oliphant CM, Green GM. Quinolones: a comprehensive review. Am Fam Physician 2002; 65(3): 455-64.
5. Somasundaram S, Manivannan K. An Overview of Fluoroquinolones. Ann Rev Res Biol 2013; 3(3): 296-313.
6. Sousa J, Alves G, Abrantes J, Fortuna A, Falcão A. Analytical methods for determination of new fluoroquinolones in biological matrices and pharmaceutical formulations by liquid chromatography: a review. Anal Bioanal Chem 2012; 403(1): 93-129.
7. Comstock TL, Paterno MR, Decory HH, Usner DW. Safety and tolerability of besifloxacin ophthalmic suspension 0. 6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies. Clin Drug Investig 2010; 30(10): 675-85.
8. Bolon MK. The newer fluoroquinolones. Infect Dis Clin N Am 2009; 23: 1027-51.
9. Giannarini G, Tascini C, Selli C. Prulifloxacin: clinical studies of a broad-spectrum quinolone agent. Future Microbiol 2009; 4(1): 13-24.
10. Sharma PC, Jain A, Jain S. Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects. Acta Pol Pharm 2009; 66(6): 587-604.
11. Matera MG. Pharmacologic characteristics of prulifloxacin. Pulm Pharmacol Ther 2006; 19(Suppl 1): 20-9.
12. Andersson MI, MacGowan AP. Development of the quinolones. J Antimicrob Chemother 2003; 51 (Suppl 1): 1-11.
13. Ball P. Adverse drug reactions: implications for the development of fluoroquinolones. J Antimicrob Chemother 2003; 51(Suppl 1): 21-7.
14. Zhanel GG, Noreddin AM. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr Opin Pharmacol 2001; 1(5): 459-63.
15. Owens RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41 (Suppl 2): S144-57.
16. Paladino JA. Is more than one quinolone needed in clinical practice? Ann Pharmacother 2001; 35(9): 1085-95.
17. Lapi F, Wilchesky M, Kezouh A, Benisty JI, Ernst P, Suissa S. Fluoroquinolones and the risk of serious arrhythmia: a populationbased study. Clin Infect Dis 2012; 55(11): 1457-65.
18. Andrade RJ, Tulkens PM. Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother 2011; 66(7): 1431-46.
19. Stahlmann R. Clinical toxicological aspects of fluoroquinolones. Toxicol Lett 2002; 127(1-3): 269-77.
20. Drug@FDA. FDA Food Drug Products [homepage on the Internet]. Available from: http://www. accessdata. fda. gov/scripts/cder/drugsatfda/index. cfm. Accessed September 5, 2013.
21. Drugs. com. Drugs Information Online [homepage on the Internet]. Available from: http://www. drugs. com. Accessed September 5, 2013.
22. Keam SJ, Perry CM. Prulifloxacin. Drugs 2004; 64(19): 2221-34.
23. Saravolatz LD, Leggett J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin Infect Dis 2003; 37(9): 1210-5.
24. Anderson DL. Sitafloxacin hydrate for bacterial infections. Drugs Today (Barc) 2008; 44(7): 489-501.
25. Sitafloxacin: DU 6859, DU 6859A, Gracevit, Sitafloxacin Hydrate. Drugs R D 2003; 4(1): 61-8.
26. Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001; 21(10 Pt 2): S253-72.
27. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999; 28(2): 352-64.
28. Stahlmann R, Lode H. Toxicity of Quinolones. Drugs 1999; 58(Suppl 2): 37-42.
29. Blondeau JM. Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Ophthalmol 2004; 49(Suppl 2): S73-8.
30. Peterson LR. Quinolone molecular structure-activity relationships: what we have learned about improvingantimicrobialactivity. Clin Infect Dis 2001; 33(Suppl 3): S180-6.
31. Rubinstein E. History of quinolones and their side effects. Chemotherapy 2001; 47(Suppl 3): 3-8.
32. Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother 2007; 41(11): 1859-66.
33. Akahane K, Sekiguchi M, Une T, Osada Y. Structureepileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites. Antimicrob Agents Chemother 1989; 33(10): 1704-8.
34. Kang J, Wang L, Chen XL, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001; 59(1): 122-6.
35. Heidelbaugh JJ, Holmstrom H. The perils of prescribing fluoroquinolones. J Fam Pract 2013; 62(4): 191-7.
36. Levaquin. Prescribing Information. Available from: http://www. accessdata. fda. gov/drugsatfda_docs/label/2013/020634 s065, 020635s071, 021721s032lbl. pdf. Accessed October 19, 2013.
37. Avelox. Prescribing Information. Available from: http://www. accessdata. fda. gov/drugsatfda_docs/label/2012/021085 s056, 021277s053lbl. pdf. Accessed August 15, 2013.
38. Factive. Prescribing Information. Available from: http://www. accessdata. fda. gov/drugsatfda_docs/label/2011/021158 s018lbl. pdf. Accessed August 15, 2013.
39. Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012; 55(Suppl 2): S65-70.
40. Novell MJ, Morreale CA. The relationship between inpatient fluoroquinolone use and Clostridium difficile-associated diarrhea. Ann Pharmacother 2010; 44(5): 826-31.
41. Edlund C, Nord CE. Effect of quinolones on intestinal ecology. Drugs 1999; 58(Suppl 2): 65-70.
42. Gopal Rao G, Mahankali Rao CS, Starke I. Clostridium difficileassociated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with beta-lactam-based therapy. J Antimicrob Chemother 2003; 51(3): 697-701.
43. Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41(9): 1254-60.
44. Biller P, Shank B, Lind L, et al. Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol 2007; 28(2): 198-201.
45. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004; 38(5): 640-5.
46. Spigaglia P, Barbanti F, Mastrantonio P, et al. Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J Med Microbiol 2008; 57(Pt 6): 784-9.
47. Dhalla IA, Mamdani MM, Simor AE, Kopp A, Rochon PA, Juurlink DN. Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease? Antimicrob Agents Chemother 2006; 50(9): 3216-9.
48. Leone R, Venegoni M, Motola D, et al. Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions. Drug Saf 2003; 26(2): 109-20.
49. De Sarro A, De Sarro G. Adverse reactions to fluoroquinolones. An overview on mechanistic aspects. Curr Med Chem 2001; 8(4): 371-84.
50. Tomé AM, Filipe A. Quinolones: review of psychiatric and neurological adverse reactions. Drug Saf 2011; 34(6): 465-88.
51. Kocyigit I, Dortdudak S, Sipahioglu M, et al. Levofloxacininduced delirium: is it a dangerous drug in patients with renal dysfunction? Ren Fail 2012; 34(5): 634-6.
52. Youssef NA, Benazzi F, Desan PH. Levofloxacin-induced catatonia. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(4): 741-2.
53. Kiangkitiwan B, Doppalapudi A, Fonder M, Solberg K, Bohner B. Levofloxacin-induced delirium with psychotic features. Gen Hosp Psychiatry 2008; 30(4): 381-3.
54. Moorthy N, Raghavendra N, Venkatarathnamma PN. Levofloxacin-induced acute psychosis. Indian J Psychiatry 2008; 50(1): 57-8.
55. Quigley CA, Lederman JR. Possible gatifloxacin-induced seizure. Ann Pharmacother 2004; 38(2): 235-7.
56. Kushner JM, Peckman HJ, Snyder CR. Seizures associated with fluoroquinolones. Ann Pharmacother 2001; 35(10): 1194-8.
57. Serafini G, Pompili M, Innamorati M, Dwivedi Y, Brahmachari G, Girardi P. Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression. Curr Pharm Des 2013; 19(10): 1898-922.
58. LaSalvia EA, Domek GJ, Gitlin DF. Fluoroquinolone-induced suicidal ideation. Gen Hosp Psychiatry 2010; 32(1): 108-10.
59. FDA Drug Safety Communication: FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection. Available from: http://www. fda. gov/Drugs/DrugSafety/ucm365050. htm. Accessed September 11, 2013.
60. Liu Y, Zhang P, Li H, Tang R, Cui R, Wang W. Photochemical properties and phototoxicity of Pazufloxacin: a stable and transient study. J Photochem Photobiol B 2013; 118: 58-65.
61. de Guidi G, Bracchitta G, Catalfo A. Photosensitization reactions of fluoroquinolones and their biological consequences. Photochem Photobiol 2011; 87: 1214-29.
62. Quintero B, Miranda MA. Mechanisms of photosensitization induced by drugs: A general survey. Ars Pharmaceutica 2000; 41(1): 27-46.
63. Lhiaubet-Vallet V, Bosca F, Miranda MA. Photosensitized DNA damage: the case of fluoroquinolones. Photochem Photobiol 2009; 85(4): 861-8.
64. Williams GM, Jeffrey AM. Oxidative DNA damage: endogenous and chemically induced. Regul Toxicol Pharmacol 2000; 32(3): 283-92.
65. Spratt TE, Schultz SS, Levy DE, Chen D, Schlüter G, Williams GM. Different mechanisms for the photoinduced production of oxidative DNA damage by fluoroquinolones differing in photostability. Chem Res Toxicol 1999; 12(9): 809-15.
66. Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging 2010; 27(3): 193-209.
67. Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009; 32(5): 359-78.
68. Lim P, Wuenschell GE, Holland V, et al. Peroxyl Radical Mediated Oxidative DNA Base Damage: Implications for Lipid Peroxidation Induced Mutagenesis. Biochemistry 2004; 43(49): 15339-48.
69. Stocker R, Keaney JF. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84(4): 1381-478.
70. Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J 2003; 17(10): 1195-214.
71. Jessup W, Kritharides L, Stocker R. Lipid oxidation in atherogenesis: an overview. Biochem Soc Trans 2004; 32(1): 134-8.
72. Collins AR, Gedik CM, Olmedilla B, Southon S, Bellizzi M. Oxidative DNA damage measured in human lymphocytes: large differences between sexes and between countries, and correlations with heart disease mortality rates. FASEB J 1998; 12(13): 1397-400.
73. Kulthanan K, Chularojanamontri L, Manapajon A, Dhana N, Jongjarearnprasert K. Cutaneous adverse reactions to fluoroquinolones. Dermatitis 2011; 22(3): 155-60.
74. Iannini P, Mandell L, Patou G, Shear N. Cutaneous adverse events and gemifloxacin: observations from the clinical trial program. J Chemother 2006; 18(1): 3-11.
75. Seto Y, Inoue R, Ochi M, Gandy G, Yamada S, Onoue S. Combined use of in vitro phototoxic assessments and cassette dosing pharmacokinetic study for phototoxicity characterization of fluoroquinolones. AAPS J 2011; 13(3): 482-92.
76. Man I, Murphy J, Ferguson J. Fluoroquinolone phototoxicity: a comparison of moxifloxacin and lomefloxacin in normal volunteers. J Antimicrob Chemother 1999; 43 (Suppl B): 77-82.
77. Zhanel GG, Ennis K, Vercaigne L et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002; 62(1): 13-59.
78. Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents 2007; 29(4): 374-9.
79. Amankwa K, Krishnan SC, Tisdale JE. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. Clin Pharmacol Ther 2004; 75(3): 242-7.
80. Briasoulis A, Agarwal V, Pierce WJ. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology 2011; 120(2): 103-10.
81. Owens RC Jr, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 2006; 43(12): 1603-11.
82. Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 2003; 73(4): 292-303.
83. Ball P, Mandell L, Patou G, Dankner W, Tillotson G. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int J Antimicrob Agents 2004; 23(5): 421-9.
84. Licata A, Randazzo C, Morreale I, Butera G, D'Alessandro N, Craxì A. Fluoroquinolone-induced liver injury: three new cases and a review of the literature. Eur J Clin Pharmacol 2012; 68(5): 525-32.
85. Adikwu E, Deo O. Fluoroquinolones Reported Hepatotoxicity. Pharmacol Pharm 2012; 3(3): 328-336.
86. Adikwu E, Brambaifa N. Ciprofloxacin Cardiotoxicity and Hepatotoxicity in Humans and Animals. Pharmacol Pharm 2012; 3: 207-13.
87. Jones DP, Lemasters JJ, Han D, Boelsterli UA, Kaplowitz N. Mechanisms of Pathogenesis in Drug Hepatotoxicity Putting the Stress on Mitochondria. Mol Interv 2010; 10(2): 98-111.
88. Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol 2008; 22(4): 335-53.
89. Figueira-Coelho J, Pereira O, Picado B, Mendonça P, Neves-Costa J, Neta J. Acute hepatitis associated with the use of levofloxacin. Clin Ther 2010; 32(10): 1733-7.
90. Shaw PJ, Ganey PE, Roth RA. Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci 2010; 118(1): 7-18.
91. Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26(7): 940-50.
92. Henann NE, Zambie MF. Gatifloxacin-associated acute hepatitis. Pharmacotherapy 2001; 21(12): 1579-82.
93. Liu HH. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf 2010; 33(5): 353-69.
94. Aspinall SL, Good CB, Jiang R, McCarren M, Dong D, Cunningham FE. Severe dysglycemia with the fluoroquinolones: a class effect? Clin Infect Dis 2009; 49(3): 402-8.
95. Lewis RJ, Mohr JF 3rd. Dysglycaemias and fluoroquinolones. Drug Saf 2008; 31(4): 283-92.
96. Saraya A, Yokokura M, Gonoi T, Seino S. Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. Eur J Pharmacol 2004; 497(1): 111-7.
97. Catero M. Dysglycemia and fluoroquinolones: are you putting patients at risk? J Fam Pract 2007; 56(2): 101-7.
98. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354(13): 1352-61.
99. Graumlich JF, Habis S, Avelino RR, et al. Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested casecontrol study. Pharmacotherapy 2005; 25(10): 1296-302.
100. Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis 2003; 36(11): 1404-10.
101. Sendzik J, Lode H, Stahlmann R. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int J Antimicrob Agents 2009; 33(3): 194-200.
102. Sendzik J, Shakibaei M, Schäfer-Korting M, Stahlmann R. Fluoroquinolones cause changes in extracellular matrix, signalling proteins, metalloproteinases and caspase-3 in cultured human tendon cells. Toxicology 2005; 212(1): 24-36.
103. Stahlmann R, Förster C, Shakibaei M, Vormann J, Günther T, Merker HJ. Magnesium deficiency induces joint cartilage lesions in juvenile rats which are identical to quinolone-induced arthropathy. Antimicrob Agents Chemother 1995; 39(9): 2013-8.
104. Schaad UB. Will fluoroquinolones ever be recommended for common infections in children? Pediatr Infect Dis J 2007; 26(10): 865-7.
105. Channa HM, Ashfaq M, Mastoi SM, Qureshi MA. Effect of ciprofoxacin on growing cartilage in albino rat pups. J Ayub Med Coll Abbottabad 2006; 18(3): 50-4.
106. Stahlmann R. Children as a special population at risk-quinolones as an example for xenobiotics exhibiting skeletal toxicity. Arch Toxicol 2003; 77(1): 7-11.
107. Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use--safety report. Pediatr Infect Dis J 1997; 16(1): 127-9.
108. Noel GJ, Bradley JS, Kauffman RE, et al. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J 2007; 26(10): 879-91.
109. Pichichero ME, Arguedas A, Dagan R, et al. Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure. Clin Infect Dis 2005; 41(4): 470-8.
110. Tsai WC, Yang YM. Fluoroquinolone-associated tendinopathy. Chang Gung Med J 2011; 34(5): 461-7.
111. van der Linden PD, van de Lei J, Nab HW, Knol A, Stricker BH. Achilles tendinitis associated with fluoroquinolones. Br J Clin Pharmacol 1999; 48(3): 433-7.
112. van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HG, Stricker BH. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002; 324(7349): 1306-7.
113. Wise BL, Peloquin C, Choi H, Lane NE, Zhang Y. Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. Am J Med 2012; 125(12): e23-28.
114. Thompson AM. Ocular toxicity of fluoroquinolones. Clin Experiment Ophthalmol 2007; 35(6): 566-77.
115. Al-Amri AM. Corneal perforation associated with topically applied gatifloxacin. Cornea 2008; 27(3): 370-1.
116. Pollock GA, McKelvie PA, McCarty DJ, White JF, Mallari PL, Taylor HR. In vivo effects of fluoroquinolones on rabbit corneas. Clin Experiment Ophthalmol 2003; 31(6): 517-21.
117. Han DP, Szabo A. Flashes, floaters, and oral fluoroquinolones: is retinal detachment a worry? JAMA Ophthalmol 2013; 131(1): 91-3.
118. Fraunfelder FW, Fraunfelder FT. Diplopia and fluoroquinolones. Ophthalmology 2009; 116(9): 1814-7.
119. Silver LH, Woodside AM, Montgomery DB. Clinical safety of moxifloxacin ophthalmic solution 0. 5% (VIGAMOX) in pediatric and nonpediatric patients with bacterial conjunctivitis. Surv Ophthalmol 2005; 50(Suppl 1): S55-63.
120. Hwang DG, Schanzlin DJ, Rotberg MH, Foulks G, Raizman MB; Levofloxacin Bacterial Conjunctivitis Place-controlled Study Group. A phase III, placebo controlled clinical trial of 0. 5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Br J Ophthalmol 2003; 87(8): 1004-9.
121. Benitez-Del-Castillo J, Verboven Y, Stroman D, Kodjikian L. The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis. Clin Drug Investig 2011; 31(8): 543-57.
122. Iquix. Prescribing Information. Available from: http://www. access data. fda. gov/drugsatfda_docs/label/2004/21571_iquix_lbl. pdf. Accessed October 8, 2013.
123. Quixin. Prescribing Information. Available from: http://www. acce ssdata. fda. gov/drugsatfda_docs/label/2002/21199s003lbl. pdf. Accessed October 8, 2013.
124. Zymar. Prescribing Information. Available from: http://www. acce ssdata. fda. gov/drugsatfda_docs/label/2005/021493s006, 007lbl. pdf. Accessed October 8, 2013.
125. Vigamox. Prescribing Information. Available from: http://www. ac cessdata. fda. gov/drugsatfda_docs/label/2011/021598s017lbl. pdf. Accessed October 8, 2013.